Succinic Acid

Succinic Acid

SCHEMBL4876825

CC=CC=CCO.O=C(O)CCC(=O)O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
EGLN1 Q9GZT9 3/20 0.41
ALKBH5 Q6P6C2 1/20 0.41
SUCNR1 Q9BXA5 1/20 0.41
SLC15A2 Q16348 1/20 0.39
FASN P49327 1/20 0.38
SOAT1 P35610 1/20 0.36
FFAR3 O14843 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
CNR2 P34972 5/20 0.33
CNR1 P21554 3/20 0.33
PPARG P37231 2/20 0.33
OXER1 Q8TDS5 2/20 0.33
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 1/20 0.33
SLC13A3 Q8WWT9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL27962714 0.86 SOAT1 (0.38) SOAT1FFAR3CNR2CNR1PPARG
Hydrogen Peroxide SCHEMBL28051253 0.85
Glycine SCHEMBL27846420 0.84 GLRA1 (0.43) LMNASOAT1CNR2CNR1PPARG
Acetic Acid SCHEMBL330176 0.84 CNR2 (0.37) SOAT1FFAR3CNR2CNR1PPARG
Stearic Acid SCHEMBL715877 0.83 FASN (0.64) LMNAFASNPPARGMAPTOR51E2
Stearic Acid SCHEMBL1071278 0.83 FASN (0.64) LMNAFASNPPARGMAPTOR51E2
Dodecanoate SCHEMBL714246 0.83 FASN (0.64) LMNAFASNPPARGMAPTOR51E2
Palmitic Acid SCHEMBL3250351 0.83 FASN (0.64) LMNAFASNPPARGMAPTOR51E2
SCHEMBL13892466 0.83
SCHEMBL734653 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140341909-A1 CONJUGATION OF BIOMOLECULES USING DIELS-ALDER CYCLOADDITION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2014-11-20 US disclosed
US-20080008709-A1 Conjugation of biomolecules using Diels-Alder cycloaddition The Government of the U.S. as represented by the Secretary of the Dept. of Health and Human 2008-01-10 US disclosed
US-7211445-B2 Immunology, diagnosis, therapy; complex of carbohydrate and protein; immobilization THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2007-05-01 US disclosed
US-20040082067-A1 Immunology, diagnosis, therapy; complex of carbohydrate and protein; immobilization THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HLTH. AND HUMAN SERVICE 2004-04-29 US disclosed
US-6673905-B2 FOR COVALENTLY LINKING CARBOHYDRATES AND PROTEINS UNDER NEUTRAL CONDITIONS, BY ATTACHING DOUBLE BONDS TO A CARRIER PROTEIN, AND ATTACHING A CONJUGATED DIENE TO A CARBOHYDRATE HAPTEN, THEN COUPLING; VACCINES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2004-01-06 US disclosed
US-20020068818-A1 Conjugation of biomolecules using diels-alder cycloaddition POZSGAY VINCE (US) 2002-06-06 US disclosed
US-20020051788-A1 For covalently linking carbohydrates and proteins under neutral conditions, by attaching double bonds to a carrier protein, and attaching a conjugated diene to a carbohydrate hapten, then coupling; vaccines HEALTH AND HUMAN SERVICES, DEPARTMENT OF, GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, THE 2002-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140341909-A1 CONJUGATION OF BIOMOLECULES USING DIELS-ALDER CYCLOADDITION DERA, DCLRE1A, CD2BP2 LMNA 2915/4885EGLN1 3428/4885ALKBH5 3149/4885
US-20020068818-A1 Conjugation of biomolecules using diels-alder cycloaddition DERA, DCLRE1A, CD2BP2 LMNA 2915/4885EGLN1 3428/4885ALKBH5 3149/4885
US-20020051788-A1 For covalently linking carbohydrates and proteins under neutral conditions, by attaching double bonds to a carrier protein, and attaching a conjugated diene to a carbohydrate hapten, then coupling; vaccines DCLRE1A, DERA, LY96 LMNA 1314/4885EGLN1 2753/4885ALKBH5 3021/4885
US-20080008709-A1 Conjugation of biomolecules using Diels-Alder cycloaddition DERA, DCLRE1A, CD2BP2 LMNA 2915/4885EGLN1 3428/4885ALKBH5 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.